Skip to Content

Kevzara Dosage

Generic name: sarilumab 150mg in 1.14mL
Dosage form: injection, solution

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Recommended Dosage

KEVZARA may be used as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs.

The recommended dosage of KEVZARA is 200 mg once every two weeks given as a subcutaneous injection.

Reduce dose to 150 mg once every two weeks for management of neutropenia, thrombocytopenia and elevated liver enzymes [see Dosage and Administration (2.4), Warnings and Precautions (5.2) and Adverse Reactions (6.1)].

General Considerations for Administration

  • KEVZARA initiation is not recommended in patients with an absolute neutrophil count (ANC) less than 2000 per mm3, platelet count less than 150,000 per mm3, or who have ALT or AST above 1.5 times the upper limit of normal (ULN) [see Dosage and Administration (2.4) and Warnings and Precautions (5.2)].
  • Prior to initiating KEVZARA, test patients for latent tuberculosis (TB). If positive, consider treating for TB prior to KEVZARA use [see Warnings and Precautions (5.1)].
  • Avoid using KEVZARA with biological DMARDs because of the possibility of increased immunosuppression and increased risk of infection. The concurrent use of KEVZARA with biological DMARDs such as TNF antagonists, IL-1R antagonists, anti-CD20 monoclonal antibodies and selective co-stimulation modulators has not been studied.
  • Avoid KEVZARA use in patients with active infections [see Warnings and Precautions (5.1)].

Important Administration Instructions

  • KEVZARA is intended for use under the guidance of a healthcare professional. A patient may self-inject KEVZARA or the patient's caregiver may administer KEVZARA. Provide proper training to patients and/or caregivers on the preparation and administration of KEVZARA prior to use according to the Instructions for Use (IFU).
  • Allow the pre-filled syringe to sit at room temperature for 30 minutes prior to subcutaneous injection. Do not warm KEVZARA in any other way.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. KEVZARA solution should be clear and colorless to pale yellow. Do not use if the solution is cloudy, discolored or contains particles, or if any part of the pre-filled syringe appears to be damaged.
  • Instruct patients to inject the full amount in the syringe (1.14 mL), which provides 200 mg or 150 mg of KEVZARA, according to the directions provided in the IFU.
  • Rotate injection sites with each injection. Do not inject into skin that is tender, damaged, or has bruises or scars.

Dosage Modifications for Laboratory Abnormalities or Serious Infection

If a patient develops a serious infection, hold treatment with KEVZARA until the infection is controlled.

Modify dosage in case of neutropenia, thrombocytopenia or liver enzyme elevations (see Table 1). For treatment initiation criteria, see [Dosage and Administration (2.2)].

Table 1: KEVZARA Dosage Modification for Neutropenia, Thrombocytopenia, or Elevated Liver Enzymes
Low Absolute Neutrophil Count (ANC)
[see Warnings and Precautions (5.2) and Clinical Pharmacology (12.2)]
Lab Value (cells/mm3) Recommendation
ANC greater than 1000 Maintain current dosage of KEVZARA.
ANC 500–1000 Hold treatment with KEVZARA until ANC greater than 1000.
KEVZARA can then be resumed at 150 mg every two weeks and increased to 200 mg every two weeks as clinically appropriate.
ANC less than 500 Discontinue KEVZARA.
Low Platelet Count
[see Warnings and Precautions (5.2)]
Lab Value (cells/mm3) Recommendation
50,000–100,000 Hold treatment with KEVZARA until platelets greater than 100,000.
KEVZARA can then be resumed at 150 mg every two weeks and increased to 200 mg every two weeks as clinically appropriate.
Less than 50,000 If confirmed by repeat testing, discontinue KEVZARA.
Liver Enzyme Abnormalities
[see Warnings and Precautions (5.2)]
Lab Value Recommendation
ALT greater than ULN to 3 times ULN or less Consider dosage modification of concomitant DMARDs as clinically appropriate.
ALT greater than 3 times ULN to 5 times ULN or less Hold treatment with KEVZARA until ALT less than 3 times ULN.
KEVZARA can then be resumed at 150 mg every two weeks and increased to 200 mg every two weeks as clinically appropriate.
ALT greater than 5 times ULN Discontinue KEVZARA.
Hide